US15117K1034 - ADR
CELLECTIS - ADR
NASDAQ:CLLS (4/26/2024, 7:00:00 PM)
After market: 2.55 +0.04 (+1.77%)2.5056
+0.02 (+0.63%)
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
CELLECTIS - ADR
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE 75013
P: 33181691600
CEO: Andre Choulika
Employees: 345
Website: https://www.cellectis.com/
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs at ASGCT 2024...
Cette nouvelle approche d'édition pourrait être utilisée pour développer de nouveaux traitements pour les maladies métaboliques et...
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases...
NEW YORK, 10 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa...
Here you can normally see the latest stock twits on CLLS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: